In the latest episode of the “Pharmacy Friends” podcast, join health outcomes experts for a discussion about Prime’s industry-leading research into persistence and adherence of glucagon-like...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

A paragraph is a self-contained unit of a discourse in writing dealing with a particular point or idea. Paragraphs are usually an expected part of formal writing, used to organize longer prose....

Dosage and administration In the VISIONARY trial, sibeprenlimab was administered SC at a dose of 400 mg every 4 weeks and can be self-administered. Place in therapy IgAN, also known as Berger’s...

Submitted supplemental drugs brensocatib oral Manufacturer: PTC Proposed indications Friedreich's ataxia (FA) Clinical overview Mechanism of action Vatiquinone is a first-in-class selective...

Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 18)...

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...